细胞循环:解锁EZH2向疗法耐药性的关键
Rachel L Paolini1,2, George P Souroullas1,2,3
1Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
Cancer discovery
|June 3, 2024
概括
研究人员在罕见癌症中确定了对EZH2抑制的抵抗机制. 抑制细胞循环激酶,如奥罗拉激酶B (AURKB) 可以克服这种抵抗,改善恶性狂犬状瘤 (MRT) 和上皮状肉瘤 (ES) 的治疗.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 恶性形瘤 (MRT) 和上皮状瘤 (ES) 是一种罕见且具有攻击性的癌症.
- 抑制EZH2是一种针对这些癌症的向治疗方法.
- 了解耐药机制对于提高治疗疗效至关重要.
研究的目的:
- 调查MRT和ES中对EZH2抑制的抵抗机制.
- 确定潜在的治疗策略,以克服EZH2抑制剂耐药性.
主要方法:
- 这项研究分析了对EZH2抑制有抗性的瘤的遗传变化.
- 研究了RB1-E2F细胞循环途径在抵抗中的作用.
- 在临床前模型中评估了抑制细胞循环激酶,特别是光激酶B (AURKB) 的疗效.
主要成果:
- 确定了EZH2本身的遗传变化作为一种抵抗机制.
- 在RB1-E2F介导的细胞循环控制中发现的变化趋同.
- 证明抑制AURKB可以绕过EZH2抑制剂的耐药性.
- 在将EZH2抑制与AURKB抑制相结合时,显示出更强的治疗疗效.
结论:
- 在MRT和ES中EZH2抑制剂耐药性涉及遗传改变和细胞循环控制的失调.
- 准像AURKB这样的细胞循环激酶是克服抵抗的可行策略.
- 组合疗法有望在这些罕见癌症中改善治疗结果.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
What is the Cell Cycle?
6.4K
The cell cycle refers to the sequence of events occurring throughout a typical cell’s life. In eukaryotic cells, the somatic cell cycle has two stages: the interphase and the mitotic phase. During interphase, the cell grows, performs its basic metabolic functions, copies its DNA, and prepares for mitotic cell division. Then, during mitosis and cytokinesis, the cell divides its nuclear and cytoplasmic materials, respectively. This generates two daughter cells that are identical to the...
6.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K


